With growing inclination towards biomarkers, the future is there to provide lucrative opportunities with regards to antibody testing. With advancements in metabolomics, genomics, and proteomics, researchers have been able to fine tune diagnostics as well as subtypes pertaining to cancer on the basis of molecular defects.
There is also an upsurge of condition-specific biomarkers, which could help companies by getting customized kits with respect to sensitivity, usability, specificity, logistics, cost, and predict health outcomes accordingly. Antibody testing has been employed far and wide owing to ability of detecting a huge number of biomolecules showing relevance in therapeutic research and clinical research. Microfluidics immunoassays are capable of measuring the protein-based biomarkers, that too, in the miniaturized test kits. This factor would certainly expand the antibody testing market in the upcoming period. Persistence Market Research has given these facts and suggested the corrective measures to be taken in its latest market study entitled “Antibody Testing Market”.
Dispensation of Antibody Testing Market
The global antibody testing market, by product, spans kits (serological test kits (serological assay test kits and serological rapid assay kits), immunoglobulin kits (immunoglobulin assay test kits and immunoglobulin rapid assay kits), and lateral flow assay kits (lateral flow assay test kits and lateral flow rapid assay kits)), chemicals and reagents, and consumables. Application-wise, it’s pregnancy, cardiovascular diseases, autoimmune diseases, infectious diseases, oncology, endocrine diseases, diabetes, and likewise. By end-user, it’s academic and research institutes, hospitals, diagnostic laboratories, biopharmaceutical companies, and homecare settings.
Region-wise Analysis
North America holds the largest market share due to the US housing a well-established healthcare system with majority of the key players present herein. Coming to Europe, the UK rules the roost, followed by Germany. Also, an interesting fact that the UK has guidelines regarding in-vitro diagnostics in place. The Asia-Pacific is expected to witness maximum turbulence in the antibody testing market due to the densely populated countries like India and China being in maximum need of antibody testing amidst Covid-19 and later as well. Persistence Market Research has given all these details with the probable calls to action in its latest market study entitled “Antibody Testing Market”.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/31930
Competitive Landscape
Persistence Market Research has profiled the key players in antibody testing market as Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche, Agilent Technologies, DiaSorin, Zeus Scientific, Abcam plc, Trinity Biotech, Werfen (Biokit), Promega, BioLegend, Meridian Bioscience, and Bio-Techne.
Persistence Market Research has also gone further with mentioning about the developments. For instance – RMDM, in February 2020, did launch “PanTum Detect”, a blood test kit for detecting cancer at early stages. Six months later, a test kit termed as ErbaLisa Covid-19 lgG ELISA was launched by Transasia Bio-Medicals, for Indian market, in particular. Abbott, in April 2020, tabled the 3rd test kit to detect Covid-19. It’s a laboratory-based blood test. A month before, Bio-Rad Laboratories, Inc. came up with SARS CoV-2 standard. It does support validation of the laboratory assays of Covid-19 antibody testing. In November 2019, EUROIMMUN went on to display its innovations in the field of diagnostics at the time of the largest trade fair held then.
It could be inferred that…
The global antibody testing market is slated to be on the winners’ side between 2021 and 2031 – Persistence Market Research
